Background: Demyelination is a neurologic disease, usually diagnosed on the basis of clinical symptomatology and radiologic studies. Rarely, both may be deceiving and masquerading a neoplastic lesion or vice versa.
Case Description: In the present communication, we describe 2 cases with similar clinical profiles and radiologic pictures, but which turn out to be contrasting pathologic diagnoses.
Conclusions: We emphasize on histopathologic proof before initiating definitive therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.surneu.2007.09.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Abnormal body mass index is associated with risk of multiple sclerosis: A systematic review and meta-analysis.
Obes Res Clin Pract
December 2024
Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address:
Background: It is widely recognized that obesity is characterized by a chronic low-grade inflammatory condition. In the context of childhood and adolescent obesity, there is also a noteworthy correlation with elevated levels of inflammatory markers. These markers signify a proinflammatory state that may have relevance to the development of MS.
View Article and Find Full Text PDFHumoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis.
BMC Immunol
June 2024
Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, 71936-13311, Iran.
Background: For the past three years, the pandemic has had a major effect on global public health, mainly on those with underlying medical conditions, such as people living with Multiple Sclerosis. Vaccination among this group is of great importance, and the long-term impacts of vaccination and its safety on the health of these patients will continue to be revealed. Therefore, risks related to vaccination and immune response need to be assessed.
View Article and Find Full Text PDFThe neuropathobiology of multiple sclerosis.
Nat Rev Neurosci
July 2024
Institut für Neuroimmunologie und Multiple Sklerose, Zentrum für Molekulare Neurobiologie Hamburg, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Chronic low-grade inflammation and neuronal deregulation are two components of a smoldering disease activity that drives the progression of disability in people with multiple sclerosis (MS). Although several therapies exist to dampen the acute inflammation that drives MS relapses, therapeutic options to halt chronic disability progression are a major unmet clinical need. The development of such therapies is hindered by our limited understanding of the neuron-intrinsic determinants of resilience or vulnerability to inflammation.
View Article and Find Full Text PDFInflammation and physical activity in multiple sclerosis patients. A systematic review and meta-analysis.
Complement Ther Med
June 2024
Department of Public Health and Pediatrics, University of Turin, Turin, Italy.
Objectives: Due to the inflammatory nature of multiple sclerosis (MS), the most widely used therapeutic approach targets the immune response but can comprise side effects (e.g. secondary immunosuppression).
View Article and Find Full Text PDFMyelin oligodendrocyte glycoprotein antibody-associated disease with clinical presentation as multiple episodes of isolated meningeal involvement: a case report.
J Int Med Res
March 2024
Department of Neurology, Hengshui People's Hospital, Hengshui, China.
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) constitutes a group of autoimmune neuroinflammatory conditions that are characterized by positive serum MOG-immunoglobulin G antibodies. The relationship between MOGAD and immune factors remains unclear. Herein, we report a man in his early 30s who initially presented symptoms of headache and low-grade fever persisting for 20 days.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!